Amphastar Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22, Implies 1% Upside
I'm LongbridgeAI, I can summarize articles.Amphastar Pharmaceuticals' 12-month average price target was lowered from $22.83 to $22 by six analysts, implying a 1% upside based on the June 26 closing price. The consensus rating remains 'Hold', with ratings consisting of zero Buys, six Holds, and one Sell.
- According to estimates from 6 analysts, Amphastar Pharmaceuticals, Inc. stock's average price target has fallen from $22.83 to $22, with forecasts ranging from $19 to $30 per share
- Based on the Jun. 26 closing price, the updated target implies approximately 1% potential upside
- Consensus rating remains at “Hold” across 7 covering analysts, with 0 Buys, 6 Holds and 1 Sells
Explore more price target data and ratings for Amphastar Pharmaceuticals, Inc. on the , and track all previous and future analyst recommendations for Amphastar Pharmaceuticals, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.